Verastem Inc (VSTM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verastem Inc (VSTM) has a cash flow conversion efficiency ratio of -0.637x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.12 Million) by net assets ($81.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Verastem Inc balance sheet quality to measure how much of total assets are equity-financed.
Verastem Inc - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Verastem Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check VSTM cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Verastem Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verastem Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Consolidated Water Co. Ltd
F:CW2
|
0.026x |
|
West Bancorporation
NASDAQ:WTBA
|
0.048x |
|
Strata Critical Medical, Inc.
NASDAQ:SRTA
|
0.012x |
|
Sprout Social Inc
NASDAQ:SPT
|
0.117x |
|
Hampidjan hf
IC:HAMP
|
0.016x |
|
Savita Oil Technologies Limited
NSE:SOTL
|
0.054x |
|
Henan Jindan Lactic Acid Technology
SHE:300829
|
0.052x |
|
GuangDong GenSho Logistics Co
SHG:603813
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Verastem Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of Verastem Inc from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see VSTM market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $57.20 Million | $-137.51 Million | -2.404x | -166.30% |
| 2024-12-31 | $-28.89 Million | $-104.77 Million | 3.626x | +340.63% |
| 2023-12-31 | $57.37 Million | $-86.46 Million | -1.507x | -12.16% |
| 2022-12-31 | $47.39 Million | $-63.67 Million | -1.344x | -119.88% |
| 2021-12-31 | $87.56 Million | $-53.50 Million | -0.611x | -110.22% |
| 2020-12-31 | $115.27 Million | $-33.51 Million | -0.291x | +98.49% |
| 2019-12-31 | $7.17 Million | $-138.52 Million | -19.308x | -3120.84% |
| 2018-12-31 | $124.30 Million | $-74.52 Million | -0.599x | +39.66% |
| 2017-12-31 | $57.68 Million | $-57.31 Million | -0.994x | -143.62% |
| 2016-12-31 | $72.30 Million | $-29.48 Million | -0.408x | +8.28% |
| 2015-12-31 | $102.47 Million | $-45.56 Million | -0.445x | -6.95% |
| 2014-12-31 | $88.77 Million | $-36.90 Million | -0.416x | -85.61% |
| 2013-12-31 | $117.45 Million | $-26.30 Million | -0.224x | +10.35% |
| 2012-12-31 | $90.47 Million | $-22.60 Million | -0.250x | -131.48% |
| 2011-12-31 | $-12.77 Million | $-10.13 Million | 0.794x | +878.28% |
| 2010-12-31 | $3.24 Million | $-330.00K | -0.102x | -- |
About Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAP… Read more